---
title: "Asieris Pharmaceuticals released its semi-annual performance, with a net loss attributable to the parent company of 162 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254997409.md"
description: "According to the Zhitong Finance APP, Asieris disclosed its semi-annual report for 2025, stating that the company achieved revenue of 130 million yuan during the reporting period, a year-on-year increase of 61.80%; the net profit attributable to the parent company was a loss of 162 million yuan; the net profit excluding non-recurring gains and losses was a loss of 177 million yuan; basic earnings per share were -0.29 yuan"
datetime: "2025-08-28T11:48:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254997409.md)
  - [en](https://longbridge.com/en/news/254997409.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254997409.md)
generator: "portal-rs"
---

# Asieris Pharmaceuticals released its semi-annual performance, with a net loss attributable to the parent company of 162 million yuan

According to the Zhitong Finance APP, Asieris (688176.SH) disclosed its semi-annual report for 2025, reporting revenue of 130 million yuan, a year-on-year increase of 61.80%; a net loss attributable to shareholders of 162 million yuan; a net loss of 177 million yuan after deducting non-recurring items; and a basic earnings per share of -0.29 yuan

### Related Stocks

- [688176.CN](https://longbridge.com/en/quote/688176.CN.md)

## Related News & Research

- [BeOne says FDA approves Tevimbra-based first-line regimen for HER2+ gastroesophageal cancer](https://longbridge.com/en/news/296930925.md)
- [Across the country, Kennedy touts MAHA, but not vaccines](https://longbridge.com/en/news/296685679.md)
- [Subscribe for Symbiotec Pharmalab Ltd IPO; Ajcon Global](https://longbridge.com/en/news/296742246.md)
- [SP Group corrects disclosure, names Schur Finance as buyer of 31,500 shares at DKK 485](https://longbridge.com/en/news/296803384.md)
- [CanSinoBIO, deepGeneAI sign framework pact to develop personalized mRNA cancer vaccines](https://longbridge.com/en/news/296884268.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**